Ivabradine improves coronary flow reserve in patients with stable coronary artery disease

Skalidis, Emmanouil; Hamilos, Michalis; Chlouverakis, Gregory; Zacharis, E.; Vardas, Panos

doi:10.1016/j.atherosclerosis.2010.11.035

Cited by 58 publications

(38 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has previously been shown that ivabradine treatment significantly increases hyperemic coronary flow velocity but reduces resting coronary blood flow velocity, and that resting coronary blood flow velocity returns to the pre-treatment values after heart rate correction [29]. These findings also support our results.…”

Section: Limitationssupporting

confidence: 94%

Myocardial perfusion at rest in patients with Diabetes Mellitus Type 1 compared with healthy controls assessed with Multi Detector Computed Tomography

Byrne

Jensen

Hjortkjær

et al. 2015

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Section: Limitationssupporting

confidence: 94%

Myocardial perfusion at rest in patients with Diabetes Mellitus Type 1 compared with healthy controls assessed with Multi Detector Computed Tomography

Byrne

Jensen

Hjortkjær

et al. 2015

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

“…In patients with stable CAD, this drug has been shown to improve CFR. 139 A small study of 46 patients showed improvement in angina severity in those with CMD and no obstructive CAD. 140 In patients with refractory angina, nontraditional forms of pharmacotherapy are implemented, in addition to the ongoing regimen.…”

Section: Reviewsmentioning

confidence: 98%

Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy

et al. 2015

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of death worldwide. In the presence of signs and symptoms of myocardial ischaemia, women are more likely than men to have no obstructive coronary artery disease (CAD). Women have a greater burden of symptoms than men, and are often falsely reassured despite the presence of ischaemic heart disease because of a lack of obstructive CAD. Coronary microvascular dysfunction should be considered as an aetiology for ischaemic heart disease with signs and symptoms of myocardial ischaemia, but no obstructive CAD. Coronary microvascular dysfunction is defined as impaired coronary flow reserve owing to functional and/or structural abnormalities of the microcirculation, and is associated with an adverse cardiovascular prognosis. Therapeutic lifestyle changes as well as antiatherosclerotic and antianginal medications might be beneficial, but clinical outcome trials are needed to guide treatment. In this Review, we discuss the prevalence, presentation, diagnosis, and treatment of coronary microvascular dysfunction, with a particular emphasis on ischaemic heart disease in women.

show abstract

“…In patients with stable CAD, it is found to improve CFR. 109 Another study showed improvement in symptoms, but no effect on coronary microvascular function. 107 Ivabradine may have a therapeutic role in CMD patients.…”

Section: Invasive Testingmentioning

confidence: 99%

Coronary Microvascular Dysfunction　― Epidemiology, Pathogenesis, Prognosis, Diagnosis, Risk Factors and Therapy ―

Chen

Wei

AlBadri

et al. 2017

Circ J

View full text Add to dashboard Cite

Angina has traditionally been thought to be caused by obstructive coronary artery disease (CAD). However, a substantial number of patients with angina are found to not have obstructive CAD when undergoing coronary angiography. A significant proportion of these patients have coronary microvascular dysfunction (CMD), characterized by heightened sensitivity to vasoconstrictor stimuli and limited microvascular vasodilator capacity. With the advent of non-invasive and invasive techniques, the coronary microvasculature has been more extensively studied in the past 2 decades. CMD has been identified as a cause of cardiac ischemia, in addition to traditional atherosclerotic disease and vasospastic disease. CMD can occur alone or in the presence obstructive CAD. CMD shares many similar risk factors with macrovascular CAD. Diagnosis is achieved through detection of an attenuated response of coronary blood flow in response to vasodilatory agents. Imaging modalities such as cardiovascular magnetic resonance, positron emission tomography, and transthoracic Doppler echocardiography have become more widely used, but have not yet completely replaced the traditional intracoronary vasoreactivity testing. Treatment of CMD starts with lifestyle modification and risk factor control. The use of traditional antianginal, antiatherosclerotic medications and some novel agents may be beneficial; however, clinical trials are needed to assess the efficacy of the pharmacologic and non-pharmacologic therapeutic modalities. In addition, studies with longer-term follow-up are needed to determine the prognostic benefits of these agents. We review the epidemiology, prognosis, pathogenesis, diagnosis, risk factors and current therapies for CMD.

show abstract

Ivabradine improves coronary flow reserve in patients with stable coronary artery disease

Cited by 58 publications

References 24 publications

Myocardial perfusion at rest in patients with Diabetes Mellitus Type 1 compared with healthy controls assessed with Multi Detector Computed Tomography

Myocardial perfusion at rest in patients with Diabetes Mellitus Type 1 compared with healthy controls assessed with Multi Detector Computed Tomography

Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy

Coronary Microvascular Dysfunction　― Epidemiology, Pathogenesis, Prognosis, Diagnosis, Risk Factors and Therapy ―

Contact Info

Product

Resources

About

Ivabradine improves coronary flow reserve in patients with stable coronary artery disease

Cited by 58 publications

References 24 publications

Myocardial perfusion at rest in patients with Diabetes Mellitus Type 1 compared with healthy controls assessed with Multi Detector Computed Tomography

Myocardial perfusion at rest in patients with Diabetes Mellitus Type 1 compared with healthy controls assessed with Multi Detector Computed Tomography

Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy

Coronary Microvascular Dysfunction ― Epidemiology, Pathogenesis, Prognosis, Diagnosis, Risk Factors and Therapy ―

Contact Info

Product

Resources

About

Coronary Microvascular Dysfunction　― Epidemiology, Pathogenesis, Prognosis, Diagnosis, Risk Factors and Therapy ―